D967Y00001

Research code: D967Y00001
Research name: Phase Ib multicentre open-label, dose-escalation research evaluating the safety and tolerability of trastuzumab derukstecan (T-DXd) and durvalumab in combination with cisplatin, carboplatin or pemetrexed in the first-line treatment of patients with advanced or disseminated non-squamous non-small cell lung cancer and human epidermal growth factor receptor type 2 (HER2+) overexpression (DESTINY-Lung03).
Indication: lung cancer
Principal researcher: Ewa Chmielowska, MD, PhD
Research population: lung cancer patients, HER2 positive
Investigated drug: enhertu ( + immunotherapy)